SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC)

Stock Information for SCYNEXIS Inc.

Loading

Please wait while we load your information from QuoteMedia.